Refreshed just now
FDA sets up council for post-market review of vaccines, gene therapies
Why it’s here: FDA formalizing a post-market safety council for vaccines and gene therapies is a federal regulatory action squarely within the biotechnology policy area.
Trace across the boardItem
2d agoYahooFDA sets up council for post-market review of vaccines, gene therapiesFDA established the CBER Safety Council within its biologics center to formalize independent post-market safety review of approved vaccines, gene therapies and blood products, replacing the existing Safety Working Group.1 outletBiotech23 linked
Connected
23 links- HillCRS Report: Novel Gene Therapies for Blood DisordersBoth involve Food and Drug Administration, Center for Biologics Evaluation and Research, Centers for Disease Control and Prevention
- HillEarly-Phase IND Protocol Recommendations for Solid Tumors; Draft Guidance for Industry; AvailabilityBoth involve Food and Drug Administration, Center for Biologics Evaluation and Research
- NewsWhite House pulls FDA nominee Heidi Overton after wavering support from Senate RepublicansBoth involve Food and Drug Administration, Centers for Disease Control and Prevention
- MoneyTranslational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinical Trial Not Allowed)Both involve Food and Drug Administration, National Institutes of Health
- NewsAre Our Medical Supplies Safe From Cyberattacks? What France’s Blood Bank Hack Means For The U.S.Both involve Food and Drug Administration, Centers for Disease Control and Prevention
- HillStrategic Planning: FDA Could Further Strengthen Robust IT Modernization PlanBoth involve Food and Drug Administration
- NewsSTAT+: 7 burning questions about the FDA’s post-Overton futureBoth involve Food and Drug Administration
- NewsFDA warns against online weight-loss drugs containing uncertain ingredientsBoth involve Food and Drug Administration
- NewsUS FDA orders new eye risk warnings for Ozempic, ZepboundBoth involve Food and Drug Administration
- NewsSTAT+: FDA warns GLP-1 drugs carry potential risk of rare eye conditionBoth involve Food and Drug Administration
- HillComments due: Robotically-Assisted Surgical Devices - Premarket Submissions; Draft Guidance for Industry and Food and Drug Administration Staff; Draft GuidanceBoth involve Food and Drug Administration
- HillComments due: Public Workshop: Evaluating Benefit-Risk in Robotic Medical Devices with Autonomous or Remote Teleoperation CapabilitiesBoth involve Food and Drug Administration
- HillComments due: Potency Assessment of Active Immunotherapy Products; Draft Guidance for IndustryBoth involve Food and Drug Administration
- HillComments due: Evaluating Benefit-Risk in Robotic Medical Devices with Autonomous or Remote Teleoperation Capabilities: Discussion Paper and Request for FeedbackBoth involve Food and Drug Administration
- HillComments due: Individualized Human Genome Editing Products: Considerations for BLA Submission and Postapproval Management; Draft Guidance for IndustryBoth involve Food and Drug Administration
- HillComments due: FDA Scientific Public Workshop: Next-Generation Sequencing for Adventitious Agent Detection in BiologicsBoth involve Food and Drug Administration
- HillComments due: BsUFA III Future Needs for the Development of Interchangeable Products; Post-Workshop Strategy DocumentBoth involve Food and Drug Administration
- HillComments due: Early-Phase IND Protocol Recommendations for Solid Tumors; Guidance for Industry - Draft GuidanceBoth involve Food and Drug Administration
- HillMoolenaar to FDA: "Chinese Clinical Data Poses Real Risks for Patients"Both involve Food and Drug Administration
- NewsSTAT+: FDA rejects lung cancer treatment ivonescimab from Summit TherapeuticsBoth involve Food and Drug Administration
- NewsSTAT+: FDA rejects Capricor Therapeutics’ Duchenne therapy, a decision that was a long time comingBoth involve Food and Drug Administration
- NewsCancer Vaccines Are Advancing. Can Regulators Keep Up?Both involve Food and Drug Administration
- HillComments due: PSG_218436 - Draft Guidance on RemibrutinibBoth involve Food and Drug Administration
About
- Food and Drug Administration
- Center for Biologics Evaluation and Research
- National Institutes of Health
- Centers for Disease Control and Prevention